atazanavir has been researched along with HIV in 2 studies
*HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brieger, M; Furfine, ES; Hazen, RJ; Kaldor, I; Miller, JF; Reynolds, D; Sherrill, RG; Spaltenstein, A | 1 |
| Arvidsson, PI; Govender, P; Govender, T; Honarparvar, B; Kruger, HG; Maguire, GE; Makatini, MM; Petzold, K; Sayed, Y; Soliman, ME; Sriharsha, SN | 1 |
2 other study(ies) available for atazanavir and HIV
| Article | Year |
|---|---|
Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.
Topics: Animals; Anti-HIV Agents; Dogs; Drug Resistance, Multiple, Viral; HIV; HIV Protease Inhibitors; Inhibitory Concentration 50; Mutation; Rats; Structure-Activity Relationship; Virus Replication | 2005 |
Pentacycloundecane-based inhibitors of wild-type C-South African HIV-protease.
Topics: Alkanes; Binding Sites; Catalytic Domain; Computer Simulation; Genotype; HIV; HIV Protease; HIV Protease Inhibitors; Humans; South Africa | 2011 |